130 related articles for article (PubMed ID: 30036351)
21. Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
Pan A; Reingold RE; Zhao JL; Moy A; Kraehenbuehl L; Dranitsaris G; McBride SM; Scher HI; Kollmeier MA; Xiao H; Rathkopf DE; Lacouture ME
J Urol; 2022 May; 207(5):1010-1019. PubMed ID: 35020444
[TBL] [Abstract][Full Text] [Related]
22. Concerns about Provenge simmer as CMS ponders coverage.
Goozner M
J Natl Cancer Inst; 2011 Feb; 103(4):288-9. PubMed ID: 21303996
[No Abstract] [Full Text] [Related]
23. Apalutamide and Metastasis-free Survival in Prostate Cancer.
Rachner TD; Tsourdi E; Hofbauer LC
N Engl J Med; 2018 Jun; 378(26):2541-2. PubMed ID: 29952180
[No Abstract] [Full Text] [Related]
24. Apalutamide and Metastasis-free Survival in Prostate Cancer.
Smith MR; Yu MK; Small EJ
N Engl J Med; 2018 Jun; 378(26):2542. PubMed ID: 29949495
[No Abstract] [Full Text] [Related]
25. Editorial Comment to Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
Sakamoto S
Int J Urol; 2021 Mar; 28(3):288. PubMed ID: 33327040
[No Abstract] [Full Text] [Related]
26. Atrasentan for metastatic hormone refractory prostate cancer.
Murphy G
Issues Emerg Health Technol; 2005 Dec; (77):1-4. PubMed ID: 16544441
[TBL] [Abstract][Full Text] [Related]
27. Immune-boosting prostate cancer vaccine endorsed by FDA advisors.
McBride D
ONS Connect; 2007 Jul; 22(7):19. PubMed ID: 17694780
[No Abstract] [Full Text] [Related]
28. Abiraterone and MVD3100 take androgen deprivation to a new level.
Schmidt C
J Natl Cancer Inst; 2011 Feb; 103(3):175-6. PubMed ID: 21242338
[No Abstract] [Full Text] [Related]
29. Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Heinrich D; Russnes KM; Oldenburg J
Eur Urol; 2018 Aug; 74(2):236-237. PubMed ID: 29691083
[No Abstract] [Full Text] [Related]
30. Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Haidl F; Heidenreich A; Pfister D
Eur Urol; 2018 Aug; 74(2):237-238. PubMed ID: 29653884
[No Abstract] [Full Text] [Related]
31. Filling a True Unmet Need: A New Therapy for Nonmetastatic Castrate-resistant Prostate Cancer Commentary on: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Kesch C; Black PC
Urology; 2018 Jun; 116():1-2. PubMed ID: 29596865
[No Abstract] [Full Text] [Related]
32. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and biological evaluation of deuterated apalutamide with improved pharmacokinetic profiles.
Pang X; Wang Y; Chen Y
Bioorg Med Chem Lett; 2017 Jun; 27(12):2803-2806. PubMed ID: 28478926
[TBL] [Abstract][Full Text] [Related]
34. Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.
Dagher R; Li N; Abraham S; Rahman A; Sridhara R; Pazdur R
Clin Cancer Res; 2004 Dec; 10(24):8147-51. PubMed ID: 15623588
[TBL] [Abstract][Full Text] [Related]
35. Apalutamide for Metastatic, Hormone-Responsive Prostate Cancer.
Klotz L
N Engl J Med; 2019 Jul; 381(1):84-86. PubMed ID: 31269371
[No Abstract] [Full Text] [Related]
36. Apalutamide-induced severe interstitial lung disease: A report of two cases from Japan.
Kobe H; Tachikawa R; Masuno Y; Matsunashi A; Murata S; Hagimoto H; Tomii K
Respir Investig; 2021 Sep; 59(5):700-705. PubMed ID: 34144936
[TBL] [Abstract][Full Text] [Related]
37. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).
Jung ME; Ouk S; Yoo D; Sawyers CL; Chen C; Tran C; Wongvipat J
J Med Chem; 2010 Apr; 53(7):2779-96. PubMed ID: 20218717
[TBL] [Abstract][Full Text] [Related]
38. Talazoparib (Talzenna) for prostate cancer.
Med Lett Drugs Ther; 2023 Aug; 65(1682):e134-e135. PubMed ID: 37541769
[No Abstract] [Full Text] [Related]
39. Leuprolide implant approved for once-yearly palliative treatment of advanced prostate cancer.
Oncology (Williston Park); 2000 Jun; 14(6):828, 830. PubMed ID: 10887633
[No Abstract] [Full Text] [Related]
40. New drug approvals for prostate cancer.
Tannock IF
Clin Adv Hematol Oncol; 2024 Jun; 22(5):245-246. PubMed ID: 38805317
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
